Safety and pharmacokinetics of intravitreal 2-methoxyestradiol implants in normal rabbit and pharmacodynamics in a rat model of choroidal neovascularization.

Choroidal neovascularization (CNV) is the leading cause of severe vision loss associated with age-related macular degeneration. As the pathogenesis of CNV formation is better understood, mechanism-based therapies, including the use of antiangiogenesis inhibitors, have been investigated. 2-methoxyestradiol (2ME2), an endogenous metabolite of estradiol, has been shown in the chick allantoic membrane model and the corneal micropocket assay to have antiangiogenic properties. The authors sought to determine the safety and pharmacokinetics of sustained-release intravitreal 2ME2 implants in normal rabbit and their efficacy in a rat model of CNV. 2ME2 implants were constructed using two designs: implant A, a silicone-based reservoir implant for the rabnbit eye, and implant B, a microimplant matrix design for the rat eye. In vitro release rates of both implants were determined. New Zealand white (NZW) rabbits had implant A placed in the vitreous cavity of one eye and the ocular toxicity was evaluated by clinical examination, serial electroretinography (ERG), and histopathology over a 28 week period. The steady state clearance of 2ME2 in the rabbit eye was calculated from in vivo release rates divided by steady state vitreous concentrations. A CNV model in the Brown-Norway rat was performed by injecting an adenoviral vector encoding human vascular endothelial growth factor in the subretinal space. Following the injection, a 2ME2 or sham (no drug) microimplant was placed in the vitreous cavity. Animals were killed over a 3 week period and the eyes examined for CNV by histopathology. Results showed that following a short burst, the release rate of implant A followed zero-order kinetics, typical of reservoir devices, and the cumulative release of implant B was proportional to the square root of time, as expected for a matrix delivery device. The safety studies in normal rabbit showed no ocular toxicities by clinical examination, ERG, and histopathology. Pharmacokinetic evaluation in the rabbit showed mean 2ME2 vitreous levels within the therapeutic range for the inhibition of endothelial cell proliferation. The experimental rat model showed a significant reduction in CNV in eyes treated with the 2ME2 implant. In conclusion, sustained-release 2ME2 intravitreal implants, which can be designed to deliver potentially therapeutic vitreous levels of 2ME2 for an extended period of time, appeared to be safe in normal rabbit and effective in a rat model of CNV. Sustained-release 2ME2 intravitreal implants may hold promise in the treatment of recurrent CNV refractory to standard therapy.

[1]  R. Nussenblatt,et al.  Pharmacokinetics and toxicity of intravitreal chemotherapy for primary intraocular lymphoma. , 2001, Archives of ophthalmology.

[2]  G. Jaffe,et al.  Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device. , 2000, Investigative ophthalmology & visual science.

[3]  K. Csaky,et al.  Choroidal neovascularization in the rat induced by adenovirus mediated expression of vascular endothelial growth factor. , 2000, Investigative ophthalmology & visual science.

[4]  K. Fujioka,et al.  Development of a new drug delivery system for protein drugs using silicone (II). , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[5]  P. Constantinides,et al.  Formulation Development and Antitumor Activity of a Filter-Sterilizable Emulsion of Paclitaxel , 2000, Pharmaceutical Research.

[6]  S. J. Green,et al.  A Good Estrogen , 1998, Science.

[7]  G. Juhász,et al.  Glucocorticoids alter recovery processes in the rat retina , 1998, Neuroreport.

[8]  L. Aiello,et al.  Vascular endothelial growth factor and the eye: biochemical mechanisms of action and implications for novel therapies. , 1998, Ophthalmic research.

[9]  R. Lukaszew,et al.  Impaired hyaloidal circulation function and uncoordinated ocular growth patterns in experimental retinopathy of prematurity. , 1998, Investigative ophthalmology & visual science.

[10]  T. Yue,et al.  2-Methoxyestradiol, an endogenous estrogen metabolite, induces apoptosis in endothelial cells and inhibits angiogenesis: possible role for stress-activated protein kinase signaling pathway and Fas expression. , 1997, Molecular pharmacology.

[11]  William Arbuthnot Sir Lane,et al.  Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.

[12]  P. A. Pearson,et al.  Evaluation of a delivery system providing long-term release of cyclosporine. , 1996, Archives of ophthalmology.

[13]  R. D'Amato,et al.  2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[14]  Michael S. Pepper,et al.  The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth , 1994, Nature.

[15]  W R Green,et al.  Age-related Macular Degeneration Histopathologic Studies: The 1992 Lorenz E. Zimmerman Lecture , 1993, Ophthalmology.

[16]  R P Murphy,et al.  Natural course of poorly defined choroidal neovascularization associated with macular degeneration. , 1988, Archives of ophthalmology.

[17]  P. Campochiaro,et al.  Retinal pigment epithelial cells release inhibitors of neovascularization. , 1987, Ophthalmology.

[18]  Richard W. Baker,et al.  Controlled Release of Biologically Active Agents , 1987 .

[19]  S. Ryan,et al.  The role of retinal pigment epithelium in the involution of subretinal neovascularization. , 1986, Investigative ophthalmology & visual science.

[20]  F. Ferris,et al.  Age-related macular degeneration and blindness due to neovascular maculopathy. , 1984, Archives of ophthalmology.

[21]  T. Zimmerman,et al.  Reports: ERG in Human Eyes following Oral Adrenocorticoids , 1973 .

[22]  G. Swartz,et al.  2-Methoxyestradiol: an Endogenous Antiangiogenic and Antiproliferative Drug Candidate , 2004, Cancer and Metastasis Reviews.

[23]  R. D'Amato,et al.  Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. , 1997, Cancer research.

[24]  R. Bunge,et al.  Controlled release of testosterone using silicone rubber. , 1973, Journal of biomedical materials research.